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B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a genetically
heterogeneous blood cancer characterized by abnormal expansion of imma-
ture B cells. Although intensive chemotherapy provides high cure rates in a
majority of patients, subtypes harboring certain genetic lesions, such as
MLL rearrangements or BCR-ABL1 fusion, remain clinically challenging,
necessitating a search for other therapeutic approaches. Herein, we aimed
to validate antioxidant enzymes of the thioredoxin system as potential ther-
apeutic targets in BCP-ALL. We observed oxidative stress along with aber-
rant expression of the enzymes associated with the activity of thioredoxin
antioxidant system in BCP-ALL cells. Moreover, we found that auranofin
and adenanthin, inhibitors of the thioredoxin system antioxidant enzymes,
effectively kill BCP-ALL cell lines and pediatric and adult BCP-ALL pri-
mary cells, including primary cells cocultured with bone marrow-derived
stem cells. Furthermore, auranofin delayed the progression of leukemia in
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doi:10.1002/1878-0261.12476 MLL-rearranged patient-derived xenograft model and prolonged the sur-
vival of leukemic NSG mice. Our results unveil the thioredoxin system as a
novel target for BCP-ALL therapy, and indicate that further studies assess-
ing the anticancer efficacy of combinations of thioredoxin system inhibitors
with conventional anti-BCP-ALL drugs should be continued.
1. Introduction
B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) is an aggressive malignancy associated with
abnormal expansion of immature B cells. The molecu-
lar background of BCP-ALL is heterogeneous, and
some known genetic aberrations that define genetic
subtypes of the disease, including breakpoint cluster
region-Abelson kinase 1 (BCR-ABL1) translocation,
mixed lineage leukemia gene rearrangements (MLLr),
hypodiploidy, and BCR-ABL-like subtype, are associ-
ated with poor prognosis (Hunger and Mullighan,
2015). Although the outcome of both childhood and
adult BCP-ALL has been substantially improved after
the introduction of risk-adapted therapy, treatment of
high-risk cytogenetic subtypes still remains a clinical
challenge, for which novel therapeutic approaches are
needed (O’Dwyer and Liesveld, 2017).
Targeting metabolic pathways aberrantly activated
in malignant cells is recently emerging as a promising
anticancer strategy. During tumorigenesis, activation
of oncogenes, and increased metabolism and prolifera-
tion rate result in elevated production of reactive oxy-
gen species (ROS), which contribute to redox
imbalance and oxidative stress, one of the hallmarks
of cancer cells (Glasauer and Chandel, 2014; Graczyk-
Jarzynka et al., 2017). To handle elevated ROS levels,
cancer cells upregulate antioxidant enzymes and
become reliant on these enzymes for their survival.
Major cellular antioxidant machineries include glu-
tathione (GSH) and thioredoxin (TXN) systems. TXN
system is composed of several interdependent enzymes,
such as thioredoxins (TXNs), thioredoxin reductases
(TXNRDs), and peroxiredoxins (PRDXs) (Lu and
Holmgren, 2014). TXN acts as a protein disulfide
reductase. During substrate reduction, TXN gets oxi-
dized and requires reactivation by NADPH-dependent
TXNRD. Among several known TXN substrates are
peroxiredoxins 1–5, antioxidant enzymes which cat-
alyze reduction of peroxides to water (Graczyk-Jar-
zynka et al., 2017).
Redox imbalance and oxidative stress observed in
cancer cells warrant targeting redox homeostasis in
cancer therapy. However, the effects of ROS on cancer
cells are two-sided. Moderate, controlled ROS levels
act as signaling molecules and contribute to cancer ini-
tiation and progression. On the other hand, when
ROS levels exceed the cellular antioxidant capacity,
they lead to macromolecule damage, cell cycle arrest,
and cell death (Gorrini et al., 2013). Consequently,
two opposite anticancer strategies interfering with
ROS levels are possible, antioxidant and pro-oxidant.
The former, antioxidant approach, had been widely
investigated, but the clinical benefits of these therapies
in cancer patients are limited (Gorrini et al., 2013).
The latter, pro-oxidant approach, is based on
increased basal ROS levels in cancer cells and the reli-
ance of cancer cells on ROS removal by antioxidant
enzymes (Glasauer and Chandel, 2014; Gorrini et al.,
2013; Trachootham et al., 2009). Indeed, inhibitors of
antioxidant enzymes of the TXN system selectively kill
cancer cells (Graczyk-Jarzynka et al., 2018; Klos-
sowski et al., 2012; Liu et al., 2012; Stafford et al.,
2018). The prominent examples in hematologic malig-
nancies include a TXNRD1/2 inhibitor auranofin
(AUR) and a PRDX1/2 and TXN1 inhibitor adenan-
thin (ADE). AUR is an approved, antirheumatic drug,
which showed preclinical efficacy against B-cell chronic
lymphocytic leukemia (CLL) and has been already
tested in phase 1/2 trial in CLL patients
(NCT01419691). ADE induced differentiation of
promyelocytic leukemia and demonstrated preclinical,
antileukemic activity (Liu et al., 2012).
The inhibition of the TXN system leads to cancer
cell death; however, the mechanisms and signaling
pathways mediating the death are complex. Due to the
crucial role of the TXN system in ROS removal, its
blocking leads to elevation of ROS levels, oxidative
damage, and cell death. Moreover, the anti-apoptotic
functions of some enzymes of the TXN system result
from their direct interactions with the key signaling
proteins. For instance, TXN1 interacts with the apop-
tosis signal-regulating kinase 1 (ASK1) and prevents
its pro-apoptotic signaling. PRDXs are partners of a
variety of oncogenes or tumor suppressors, such as
mitogen-activated protein kinases (MAPKs) (Kim
et al., 2006), c-MYC (Egler et al., 2005), or phos-
phatase and tensin homolog (PTEN) (Cao et al.,
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2009). Furthermore, in CLL cells, it was demonstrated
that AUR triggered endoplasmic reticulum (ER)
stress-induced apoptosis (Fiskus et al., 2014). ER
stress results from accumulation of unfolded or dam-
aged proteins in the ER, which induces unfolded pro-
tein response (UPR) signaling pathways. Triggering
UPR aims to alleviate the ER stress; however, sus-
tained, unresolved ER stress ultimately leads to apop-
tosis. UPR signaling pathways are comprehensively
described here (Moenner et al., 2007). As demon-
strated recently, inhibition of cytosolic TXNRD1 dis-
turbs folding of disulfides in the ER, establishing a
direct link between cytosolic oxidative stress and the
ER stress (Poet et al., 2017).
Although altered expression of some enzymes of
the TXN system was already observed in selected
hematologic malignancies (Agrawal-Singh et al., 2012;
Sewastianik et al., 2016; Trzeciecka et al., 2015), our
knowledge on the influence of these enzymes on can-
cer progression and response to therapy of BCP-
ALL is currently limited. In this study, we aimed to
validate antioxidant enzymes of the TXN system as
putative therapeutic targets in BCP-ALL. We provide
data on the expression of the TXN system antioxi-
dant enzymes in BCP-ALL cell lines and primary
cells and evaluate the antileukemic efficacy of the
inhibitors of these enzymes in vitro and in vivo. Fur-
thermore, we demonstrate that in BCP-ALL cells
AUR and ADE induce oxidative stress as well as
ER stress, which finally result in apoptotic cell
death.
2. Materials and methods
2.1. Cell culture
Human BCP-ALL cell lines (697, REH) and B-cell
lymphoma cell line RL were purchased from ATCC
(Manassas, VA, USA) and BCP-ALL cell lines
(SEM, SD1, BV173, SUP-B15) from DSMZ (Braun-
schweig, Germany). These cell lines represent subtypes
of BCP-ALL harboring various genetic alterations,
such as MLL-AF4 (SEM), BCR-ABL1 (BV173, SUP-
B15, SD1), E2A-PBX1 (697), and TEL-AML1
(REH). For mechanistic studies, we selected two cell
lines representing the genetic subtypes with poor
prognosis: SEM and BV173, and in selected experi-
ments also primary BCP-ALL blasts or their primo-
grafts. All cell lines were maintained in RPMI 1640
medium (Gibco, Paisley, UK) supplemented with
10% FBS (HyClone, Logan, UT, USA) and 1% peni-
cillin/streptomycin solution (Sigma-Aldrich, St. Louis,
MO, USA) in a humidified atmosphere at 37 °C and
5% CO2. The cells were routinely checked for Myco-
plasma contamination.
2.2. Chemicals
Adenanthin (Faces Biochemical Co., Wuhan, China)
and auranofin (Santa Cruz Biotechnology, Dallas, TX,
USA, and Sigma-Aldrich) were dissolved in DMSO at
10 mM concentration. All drugs were aliquoted and
stored at 20 °C. In all assays, control groups were
treated with DMSO (Sigma-Aldrich).
2.3. Leukemic patients
2.3.1. Pediatric BCP-ALL patients
In total, n = 129 childhood BCP-ALL patients of
specified cytogenetic or/and molecular ALL subtypes
were enrolled into gene expression analysis. Patients
were diagnosed and treated according to ALL IC
BFM 2009 protocol in the clinical centers of the Pol-
ish Pediatric Leukemia/Lymphoma Study Group
between August 2014 and December 2016. The
research protocol was approved by the Bioethics
Committee of the Medical University of Lodz, and
informed written consent was obtained from all par-
ticipants and/or their parents. Mononuclear leuko-
cytes were extracted from bone marrow taken for
routine diagnostic procedures and processed within
24 h. All bone marrow aspirates had more than 80%
blasts as confirmed by microscopic and flow cytome-
try analyses. Detailed characteristics of pediatric
patients enrolled into gene expression analysis are
listed in Table S3.
2.3.2. Adult BCP-ALL patients
Adult patients (n = 12) were enrolled at the Institute
of Hematology and Transfusion Medicine in Warsaw
after obtaining appropriate informed written consent
under the approval of the Bioethics Committee of
Medical University of Warsaw. Treatment and risk
stratification of the patients were carried out according
to PALG ALL6 protocol. The collected bone marrow
was processed within 24 h. The percentage of blasts in
the isolates was confirmed using flow cytometry. The
samples that contained < 80% blasts were purified
using EasySepTM Human CD19 Positive Selection Kit
(STEMCELL Technologies, Vancouver, BC, Canada).
Detailed characteristics of adult patients enrolled into
gene expression analysis are listed in Table S4. The
study methodologies conformed to the standards set
by the Declaration of Helsinki.
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2.4. Isolation of BCP-ALL patients’ serum
Blood samples were collected from pediatric BCP-ALL
patients from Pediatric Hospital of Medical University
of Warsaw [n = 35, median age = 5.57 (min–max:
1.42–16.58)] and adult BCP-ALL patients obtained
from Institute of Hematology and Transfusion Medi-
cine in Warsaw [n = 17, median age = 47 (min–max:
20–72)] under the approval of the Bioethics Committee
of Medical University of Warsaw. Control groups con-
sisted of age-related 21 pediatric and 14 adult healthy
donors. Following blood collection, the samples were
stored at room temperature for 1–4 h to form a clot
and then centrifuged at 1000 g for 10 min. Serum-con-
taining supernatants were collected and stored at
80 °C.
2.5. Isolation of normal CD19+ and CD34+ cells
Normal CD19+ and CD34+ cells were isolated from
healthy donors’ peripheral blood obtained from Regio-
nal Blood and Hemotherapy Center in Warsaw. Nor-
mal peripheral blood mononuclear cells (normal
PBMC) were isolated using density gradient medium –
LymphoprepTM (1.077 gmL1; Axis-Shield, Oslo, Nor-
way). Subsequently, CD19+ cells were isolated with
EasySepTM Human CD19 Positive Selection Kit
(STEMCELL Technologies), and CD34+ cells with
EasySepTM Human CD34 Positive Selection Kit
(STEMCELL Technologies). Germinal center B cells
(GC B cells) were isolated as described previously
(Trzeciecka et al., 2015).
2.6. Analysis of redox biomarkers in sera samples
Markers of redox homeostasis in the serum of pedi-
atric and adult BCP-ALL patients were determined
by the following assays (Diacron, Grosseto, Italy):
reactive oxygen metabolites (ROM, which quantifies
hydroperoxides by the Fenton reaction), biological
antioxidant potential (BAP, which measures the con-
centration of antioxidants as agents that can reduce
iron from the ferric to ferrous form), and protein
thiol levels (SHP, which measures all free thiol
groups in proteins), using DxC auto-analyzer (Beck-
man Coulter, Woerden, the Netherlands) as previ-
ously described (Jansen et al., 2015). These three
assays gave stable results, also after storage of serum
samples at 80 °C for longer periods (Jansen et al.,
2015). In the analysis, we included 17 adult and 35
pediatric BCP-ALL sera samples. As controls, we
used sera collected from age-matched healthy subjects
(21 pediatric and 14 adult).
2.7. Assessment of mRNA levels by qPCR in BCP-
ALL cell lines and normal CD19+ and CD34+ cells
For detection of PRDX1, TXN1, and TXNRD1
mRNA levels, BCP-ALL cell lines were seeded onto
six-well plates at 0.2 9 106 cellsmL1 density and cul-
tured for 48 h. To evaluate the GRP78 and CHOP
mRNA level, SEM cells were seeded onto six-well
plates at 0.2 9 106 cellsmL1 density and treated with
AUR and ADE for 3, 6, and 24 h. Before RNA isola-
tion, cells were washed with phosphate-buffered saline
(PBS), pelleted, and suspended in 0.5 mL of TRIzol
reagent (Roche, Mannheim, Germany). Normal
CD19+ and CD34+ cells were suspended in TRIzol
reagent directly after isolation by magnetic beads
(EasySepTM positive selection kits).
The RNA was isolated according to the manufac-
turer’s protocol. The purity and concentration of iso-
lated RNA was measured by NanoDrop 2000c
spectrophotometer (Thermo Fisher Scientific, Wal-
tham, MA, USA). Hematopoietic Progenitor Cell
(CD34+) pooled total RNA isolated from multiple
donors was also purchased from MACS (Miltenyi,
Bergisch Gladbach, Germany; cat. no. 130-093-167).
Subsequently, 0.1–0.5 lg of RNA was incubated with
DNase (Sigma-Aldrich) and used for cDNA synthesis
with the avian myeloblastosis virus (AMV) reverse
transcriptase (EURx, Gdansk, Poland) and Transcrip-
tor First Strand cDNA Synthesis Kit (Roche) for cell
lines and normal cells, respectively. Assessment of the
expression of PRDX1, TXN1, TXNRD1, GRP78,
CHOP, and RPL29 was evaluated as described previ-
ously (Muchowicz et al., 2015). The primers’ sequences
are listed in Table S5.
2.8. Assessment of mRNA levels by qPCR in
primary BCP-ALL samples
RNA from BCP-ALL pediatric patients was isolated
according to the manufacturer’s protocol (Ambion by
Life Technologies, Carlsbad, CA, USA) with addi-
tional step of DNase digestion with RNase-Free
DNase Set (Qiagen, Hilden, Germany). The concentra-
tion and quality of isolates were determined by ultravi-
olet spectrophotometry (NanoDrop 8000; Thermo
Fisher Scientific, Waltham, MA, USA). RNA from
BCP-ALL adult patients was isolated and incubated
with DNase as described for BCP-ALL cell lines. A
total of 1 lg of RNA was used for cDNA synthesis
using the High-Capacity cDNA Reverse Transcription
Kit (Thermo Fisher Scientific, Waltham, MA, USA)
and Transcriptor First Strand cDNA Synthesis Kit
(Roche) for pediatric and adult patients, respectively.
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Then, 30 ng of cDNA was used for each qPCR. The
expression of PRDX1, TXN1, TXNRD1 target genes,
and RPL29 (ribosomal protein L29) as a reference gene
was measured in duplicates by a fluorescence-based
kinetic qPCR. The reaction was performed using
Mx3000P qPCR System (Agilent Technologies, Santa
Clara, CA, USA) in combination with the intercalating
fluorescent dye Fast SYBR Green Master Mix (Thermo
Fisher Scientific, Waltham, MA, USA) in accordance
with the manufacturer’s instructions. Detailed patients’
characteristics are presented in Tables S3 and S4.
Sequences of primers designed for qPCR are listed in
Table S5. For the analysis of qPCR data, the relative
gene expressions were calculated using cycle threshold
(Ct) values and are presented as 2
DCt .
2.9. Immunoblotting
For immunoblotting, cells were lysed in a lysis buffer
(10% glycerol, 1.0% Triton X-100, 150 mM NaCl,
5 mM EDTA, 50 mM Hepes, pH 7.4) containing Com-
plete Protease Inhibitor Cocktail (Roche Diagnostics)
and Complete Phosphatase Inhibitor Cocktail (Roche
Diagnostics). Total protein concentration was accessed
using Pierce BCA Protein Assay Kit (Thermo Fisher
Scientific, Rockford, IL, USA), and subsequently 7 lg
of whole-cell protein lysates was separated in 10–15%
polyacrylamide gels. Following SDS/PAGE, proteins
were transferred to Protran nitrocellulose membranes
(Schleicher and Schuell BioScience, Dassel, Germany),
blocked in 5% nonfat dry milk or BSA, and incubated
with following primary antibodies: anti-PRDX1,
anti-TXN1, anti-TXNRD1, anti-HO-1, anti-GRP78,
anti-p-eIF2a, anti-eIF2a, anti-PARP, and anti-a-tubu-
lin, followed by the incubation with HRP-linked
secondary antibodies. More detailed information about
primary antibodies is listed in Table S6. For signal
development, SuperSignal Chemiluminescent Substrate
(Thermo Fisher Scientific, Rockford, USA) and
ChemiDoc Imaging System (Bio-Rad Laboratories,
Hercules, CA, USA) were used. Densitometric quan-
tifications were performed using IMAGE LAB Software
(Bio-Rad Laboratories).
2.10. MTT assay
To assess cytostatic/cytotoxic effects of AUR and
ADE, we used 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay.
BCP-ALL cell lines were cultured in their medium
as described above, seeded onto 96-well plates at
0.2 9 106 cellsmL1 density, and treated with drugs
at particular dose range (0.0625–2 lM for AUR and
0.125–4 lM for ADE) in a total volume of 150 lL, 4
replicates per each concentration. As a background
control, cells were exposed to 1% SDS. After 48 h,
5 mgmL1 MTT solution (Sigma-Aldrich) was added
to each well, followed by 2- to 4-h incubation, depend-
ing on a cell line. In order to dissolve formazan crys-
tals, solubilization buffer (10% SDS, 0.01 M HCl) was
added, and the next day, absorbance was measured at
560 nm using a microplate reader (ASYS UVM 340;
Biochrom, Berlin, Germany).
Primary leukemic blasts were suspended at a final
concentration of 1–2 9 106 cellsmL1 in culture med-
ium containing: RPMI 1640 (Sigma-Aldrich), 20%
FBS (Gibco, Thermo Fisher, Waltham, MA, USA),
2 mM L-glutamine, 200 mgmL1 of gentamycin, and
ITS (5 mgmL1 of insulin, 5 mgmL1 of transferrin,
and 5 ngmL1 of sodium selenite). The 10 mM stocks
of ADE and AUR were further diluted in RPMI 1640
in serial twofold dilutions, to obtain 0.0156–2 lM and
0.25–8 lM concentration ranges for AUR and ADE,
respectively. Cell suspension (80 lL) was dispensed
into 96-well microculture plates containing 20 lL of
the drug dilutions. Each drug concentration was tested
in 2–3 replicates. Positive control (cells with vehicle
alone) and blanks (medium alone) were included.
Plates were incubated in humidified incubator in 5%
CO2 at 37 °C. After 92 h, 10 lL MTT solution
(5 mgmL1 MTT in saline stored at 20 °C) was
added, and after shaking for 5 min, plates were incu-
bated for 6 h at cell culture incubator. After incuba-
tion, formazan crystals were dissolved with 100 lL of
0.04 N HCl/isopropyl alcohol (acid isopropanol). The
optical density (OD) was measured with a microplate
reader Halo MPR-96 (Dynamica Scientific, Newport
Pagnell, UK) with 550-nm filter. After the background
subtraction, OD of each sample was normalized to
untreated controls (DMSO). Viability of the cells is
presented as percentage of the controls.
Normal peripheral blood mononuclear cells (normal
PBMC) were isolated from peripheral blood of
healthy donors using density gradient medium – Lym-
phoprepTM (1.077 gmL1; Axis-Shield). Cells were
seeded onto 96-well plates at 1.0 9 106 cellsmL1
density and treated with drugs at a dose range of
0.125–2 lM for AUR and 0.25–2 lM for ADE in a
total volume of 100 lL, 4 repeats per each concentra-
tion, for 4 days. The latter steps of the assay were per-
formed as described for BCP-ALL cell lines.
2.11. ROS assessment
Assessment of ROS levels was performed using
CM-H2-DCFDA dye (Molecular Probes, Eugene, OR,
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USA) according to the manufacturer’s protocol.
Briefly, cells were seeded at 0.2 9 106 cellsmL1 den-
sity and stained with the dye for 30 minutes at 37 °C,
using 5 lM CM-H2-DCFDA for 1-, 2-, 4-, and 6-h
treatment with AUR or ADE (SEM, BV173), or
10 lM CM-H2-DCFDA for 6-h treatment (BV173).
The green fluorescence intensity of all live cells (gated
using FSC and SSC parameters) was assessed by flow
cytometry using Canto II (BD Biosciences, Franklin
Lakes, NJ, USA).
2.12. Assessment of dead cells with propidium
iodide staining
SEM and BV173 cells were seeded onto 96-well plate
at a density 0.2 9 106 cellsmL1 and pretreated with
1 mM of pyruvate for 30 min. Subsequently, cells were
treated with indicated concentrations of AUR or ADE
for 24 h and stained with propidium iodide (PI) at
final concentration of 1 lgmL1 (Sigma-Aldrich). PI-
positive cells were accessed by flow cytometry using
Canto II (BD Biosciences).
2.13. Assessment of dead cells with 7AAD
staining
Normal human PBMC and primograft BCP-ALL cells
were isolated as described above. Both normal and
malignant cells were seeded onto 12-well plates at a
density of 1 9 106 cellsmL1 and treated with 0.5 and
1.0 lM of AUR for 4 days in monoculture. Following
the treatment, PBMC were stained with anti-hCD19
and anti-hCD3 and primografts with anti-hCD19 only.
Prior to acquisition, normal and malignant cells were
stained with 7AAD (BioLegend, San Diego, CA,
USA) and analyzed by flow cytometry using Canto II
(BD Biosciences).
2.14. BM-MSC isolation and culture
Primary bone marrow-derived mesenchymal stem cells
(BM-MSC) were obtained from bone marrow of two
adult individuals (aged between 20 and 42 years) who
underwent hip replacement surgery and were isolated
according to the protocol described in Pal et al.
(2016). Prior to sample collection, an appropriate
individual written consent was obtained and an
approval was given by Bioethical Committee of Medi-
cal University of Warsaw and the Newcastle and
North Tyneside 1 Research Ethics Committee. Iso-
lated BM-MSC were cultured according to the proto-
col described in Pal et al. (2016). The identity and
quality of the BM-MSC was confirmed by the
assessment of the positive (CD73, CD105, CD90) and
negative (CD45, CD34, CD19) markers by flow
cytometry as well as by their potential to differentiate
into adipocytes, osteoblasts, and chondroblasts. Vali-
dation of isolated BM-MSC is presented in Fig. S1.
Antibodies used for flow cytometry are listed in
Table S6.
2.15. Primograft generation
Animal experiments were performed under the
approval given by Ethics Committee of the Medical
University of Warsaw. NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ, The Jackson Laboratory (NSG), mice were used
for BCP-ALL blasts’ propagation. For this purpose,
cryopreserved primary ALL samples were thawed and
2–5 9 106 cells were transplanted intrafemorally or via
tail vein injections. The whole blood staining was
performed to evaluate the engraftment of leukemic
cells. Accordingly, cells were stained with anti-mCD45,
anti-hCD45, anti-hCD19 antibodies (Table S6)
and analyzed by flow cytometry using Canto II
(BD Biosciences). The mice were humanely killed
when percentage of human blasts (hCD45+
hCD19+/mCD45+ 9 100%) in peripheral blood reached
around 100% and was accompanied by visible signs of
illness, such as inactivity and splenomegaly. Primograft
ALL cells were collected from spleens and bone mar-
rows of leukemic mice. All primografts used in ex vivo
analysis contained > 80% CD19.
2.16. Drug treatment in the BCP-ALL-MSC
coculture model
For testing drug cytotoxic/cytostatic effects, BCP-ALL
primografts were cocultured with BM-MSC (Pal et al.,
2016). To this end, BM-MSC were seeded onto 48-well
plate at a density of 2.5–5.0 9 104 cells per well, in
DMEM (low glucose) supplemented with 20% FBS
(Gibco), 2 mM of L-glutamine (Sigma-Aldrich), and
1% penicillin/streptomycin solution (Sigma-Aldrich).
The next day, BCP-ALL primograft cells were added
at a density of 0.5 9 106 cellsmL1 in SFEM II media
(STEMCELL Technologies) supplemented with 20%
FBS (Gibco), 20 ngmL1 of recombinant IL-3 (R&D
Systems, Minneapolis, MN, USA), 10 ngmL1 of
recombinant IL-7 (R&D Systems), and penicillin/strep-
tomycin solution (Sigma-Aldrich). After 24 h of cocul-
ture, cells were treated with auranofin (AUR) or
adenanthin (ADE) at indicated concentration ranges,
in a final volume of 700 lL. For each drug concentra-
tion, samples were run in duplicate. After 5 days, cells
in suspension (BCP-ALL cells) and adherent cells
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(BCP-ALL+MSC) were collected and the number of
viable cells was assessed in a hemocytometer. The
numbers of viable BCP-ALL cells in control groups
after 5-day-long coculture exceeded the number of
seeded cells, confirming the growth-supporting role of
BM-MSC. Primograft samples used in drug-testing
experiments are listed in Table S7.
2.17. In vivo experiments
All experiments involving mice were carried out
according to the EU Directive 2010/63/EU for animal
experiments and the Polish legislation on animal
experiments of the Polish Ministry of Science and
Higher Education from February 26, 2015. Mice were
maintained in SPF animal facility equipped with indi-
vidually ventilated cages. In planning, design, execu-
tion, and presenting of animal experiments, we
followed the Animal Research: Reporting of In Vivo
Experiments (ARRIVE) guidelines for reporting ani-
mal research (Kilkenny et al., 2010). All animal experi-
ments were performed under the approval of
the Ethics Committee of the Medical University of
Warsaw.
Cryopreserved primograft samples were thawed,
and 0.5 9 106 cells were transplanted through tail
vein injections to 8- to 12-week-old male and female
NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, The
Jackson Laboratory). The engraftment of the human
cells was evaluated in the whole blood collected from
cheek vein, once a week, via staining with anti-mCD45,
anti-hCD45, anti-hCD19 antibodies (Table S6). The
percentage of human blasts was determined using the
formula: (hCD45+hCD19+/mCD45+) 9 100%. When
the percentage of the human cells exceeded 1% murine
mCD45+ cells, randomly selected mice were treated
with 10 mgkg1 of auranofin or DMSO (control)
through intraperitoneal injections, once a day for
3 weeks (5 days of treatment/2 days of break schedule).
The leukemia progression was monitored once a week
by whole blood staining, as described above. The mice
were euthanized by cervical dislocation when visible
signs of sickness were observed, such as splenomegaly
or loss in hind paw reflex, in parallel with five times
higher ratio of human blasts to murine leukocytes in
the blood in two consecutive measures. No effect of sex
on the development of leukemia or on the effectiveness
of therapy was observed.
2.18. Detection of DNA oxidative damage
SEM cells were seeded onto 24-well plate in
RPMI medium supplemented with 10% FBS and
penicillin/streptomycin solution at 0.2 9 106 cellsmL1
density and subjected to AUR or ADE treatment for
24 h. BCP-ALL primografts were seeded onto 48-well
plate at a density of 1 9 106 cellsmL1 in SFEM II
medium supplemented as described above. Induction of
DNA oxidative damage was accessed by Muse H2A.X
Activation Dual Detection Kit (Merck Millipore,
Darmstadt, Germany) according to the manufacturer’s
protocol.
2.19. Detection of caspase activity
SEM cells were seeded onto 24-well plate at a density
of 0.2 9 106 cellsmL1 in their medium and exposed
to AUR for 16 h. Detection of caspase activity (cas-
pase-1, caspase-3, caspase-4, caspase-5, caspase-6, cas-
pase-7, caspase-8, and caspase-9) was performed using
Muse MultiCaspase Assay Kit (Merck Millipore) in
accordance with the manufacturer’s protocol and ana-
lyzed in Muse Cell Analyzer (Merck Millipore).
2.20. Data presentation and statistical analysis
Unless stated otherwise in Figure Legends, all the fig-
ures present averaged data from at least two indepen-
dent experiments with standard errors of the mean
(SEM). P values lower than 0.05 were considered sta-
tistically significant as measured by unpaired t-test
using GRAPHPAD7 Software (La Jolla, CA, USA) and
presented as *P < 0.05, **P < 0.01, ***P < 0.0001.
All other tests used for group comparisons are
described in detail in Figure Legends.
3. Results and Discussion
3.1. BCP-ALL cells have imbalanced redox
homeostasis
To evaluate the redox homeostasis in BCP-ALL
patients, we measured the levels of redox status-related
parameters in BCP-ALL patients’ sera collected at
diagnosis. Reactive oxygen metabolites (ROM) were
elevated in both adult and pediatric BCP-ALL sera as
compared to age-related healthy subjects (Fig. 1A, left
panel). In addition, antioxidant capacity was decreased
in pediatric BCP-ALL and free thiols were decreased
in adult and pediatric BCP-ALL sera, as measured by
biological antioxidant potential (BAP) and the number
of thiol groups in protein (SHP) assays, respectively
(Fig. 1A, middle and right panels). None of the redox
status-related parameters positively correlated with
white blood cell count (WBC) (ROM: r = 0.415 and
0.266, BAP: r = 0.046 and 0.095, SHP: r = 0.064
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and 0.005, for pediatric and adult patients, respec-
tively).
Next, we assessed the mRNA levels of the enzymes
of the TXN system by qPCR in blasts isolated from
patients diagnosed with BCP-ALL. The mean mRNA
level of PRDX1 in BCP-ALL blasts was higher com-
pared to normal CD34+ or normal peripheral blood
(PB) CD19+ cells, and the mean TXN1 and TXNRD1
levels were higher compared to normal PB CD19+
cells (Fig. 1B). The mRNA and protein levels of the
TXN system enzymes were also determined in BCP-
ALL cell lines representing different cytogenetic sub-
types of BCP-ALL and compared to normal B cells
isolated from peripheral blood (PB B cells) or from
tonsillar germinal centers (GC B cells). At mRNA
level, TXNRD1 was upregulated in all cell lines, while
TXN1 and PRDX1 were upregulated in the majority
of cell lines, as compared to normal B cells (Fig. 1C).
Fig. 1. Increased oxidative stress in BCP-ALL patients is accompanied by upregulation of TXN system antioxidant enzymes in BCP-ALL
primary cells and BCP-ALL cell lines. (A) Redox biomarkers: ROM, BAP, and total thiol levels, as determined by free SH groups in proteins
(SHP), were evaluated in the sera collected at diagnosis of BCP-ALL pediatric (n = 35) and adult (n = 17) patients and compared with age-
related healthy subjects (HS, n = 21 and n = 14 for pediatric and adult HS, respectively). P values are presented for groups with significant
differences (P < 0.05 in Mann–Whitney’s U-test). (B) mRNA levels of PRDX1, TXN1, and TXNRD1 in primary BCP-ALL blasts (in total
n = 129 pediatric ALL for PRDX1, n = 115 pediatric ALL for TXN1, TXNRD1, and n = 11 adult ALL for all genes) and in normal CD34+ (total
RNA from CD34+ cells isolated from peripheral blood of multiple donors, two independent samples) and normal CD19+ (isolated from
peripheral blood of three donors) cells. mRNA expression of the TXN system antioxidant enzymes was assessed by qPCR normalized to a
reference gene, 60S ribosomal protein L29 (RPL29), as 2DCt . Data are presented as individual values with mean  SD. P values for
comparisons between BCP-ALL patients’ groups and controls are presented (Mann–Whitney’s U-test). (C) mRNA levels of PRDX1, TXN1,
and TXNRD1 in BCP-ALL cell lines were measured with qPCR and normalized to the housekeeping genes, RPL29 and/or b2-microglobulin
(B2M). Data show mean values from at least two independent experiments + SEM and are compared with control peripheral blood (PB) B
cells and tonsillar germinal center (GC) B cells isolated from two healthy donors. *P < 0.05, ***P < 0.0001 by ANOVA with Dunnett’s
post hoc test (compared with GC B cells). (D) Representative western blot for the protein levels of TXN antioxidant enzymes in malignant B-
cell lines and normal GC B cells. Relative intensity to a-tubulin calculated by densitometry (IMAGE LAB Software; Bio-Rad Laboratories) is
presented under each band.
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At the protein level, we observed significant upregula-
tion of PRDX1 and TXN1 in a vast majority of cell
lines (Fig. 1D).
Collectively, these data demonstrate disturbed redox
homeostasis in BCP-ALL patients’ sera, associated
with increased levels of oxidative metabolites and
reduced total antioxidant capacity and free protein thi-
ols. These results are in agreement with previously
published data showing elevated levels of other oxida-
tive stress biomarkers (such as carbonylated proteins,
malondialdehyde), and reduced levels of selected
antioxidants in sera of BCP-ALL patients (Battisti
et al., 2008; Rasool et al., 2015), and substantiate the
persistence of oxidative stress in BCP-ALL patients.
Furthermore, we observed that the dysregulation of
redox homeostasis in BCP-ALL sera is accompanied
by increased expression of the TXN system antioxi-
dant enzymes in BCP-ALL cell lines and primary cells.
3.2. Inhibitors of the TXN antioxidant enzymes
are effective against BCP-ALL cell lines and
primary cells in vitro
Considering the occurrence of oxidative stress in BCP-
ALL patients along with the upregulation of the
antioxidant enzymes of the TXN system in BCP-ALL
cells, we hypothesized that in BCP-ALL these enzymes
may be components of the adaptation to the pro-oxi-
dant conditions. To address this hypothesis, we tested
the cytostatic/cytotoxic efficacy of the TXNRD inhibi-
tor auranofin (AUR) (Fiskus et al., 2014) (Fig. 2A,
upper panel) as well as the PRDX1/2 and TXN inhibi-
tor adenanthin (ADE) (Liu et al., 2012; Muchowicz
et al., 2014) (Fig. 2A, lower panel) in BCP-ALL cell
lines. Both inhibitors affected the viability of all cell
lines (Fig. 2A), with EC50 of 0.4–1.2 lM for AUR and
0.7–1.2 lM for ADE (Table S1). Moreover, AUR and
ADE decreased the viability of primary BCP-ALL
blasts grown in monoculture, with EC50 in the range
of 0.125–1.8 lM and 0.2–3.7 lM for AUR and ADE,
respectively (Fig. 2B). Boutter et al. (2014) showed the
role of bone marrow-derived mesenchymal stem cells
(BM-MSC) in promoting survival and modulating of
drug sensitivity of BCP-ALL cells by an alleviation of
oxidative stress. To test the cytostatic/cytotoxic effi-
cacy of TXN system inhibitors in the presence of
stroma, we employed an in vitro coculture model of
BCP-ALL cells with primary human BM-MSC of con-
firmed phenotype and differentiation capacity (Fig. S1)
(Pal et al., 2016). Despite stromal support and a
Fig. 2. Inhibitors of the TXN system antioxidant enzymes effectively kill BCP-ALL cell lines and primary blasts. (A) BCP-ALL cell lines were
treated with AUR and ADE at particular dose range (0.0625–2 lM for AUR and 0.125–4 lM for ADE) for 48 h and subjected to an MTT
viability assay. Viability of the cells is shown as percentage of the untreated controls (DMSO). For each drug concentration, mean value is
shown from at least two independent experiments  SEM. (B) Adult BCP-ALL cells (primary, n = 3 and primograft, n = 3) and pediatric
primary cells (n = 2) were treated with AUR (0.0156–2 lM), whereas n = 37 pediatric primary cells were treated with ADE (0.25–8 lM) in
monoculture for 4 days and subjected to MTT assay. Data are shown as EC50 of AUR and ADE, as calculated in GRAPHPAD7 (La Jolla, CA,
USA) by nonlinear regression dose–response analysis. (C) Primograft cells representing MLLr (PG2-OBL9, PG1-ALL5) and BCR-ABL1 (PG1-
OBL1, L4951, PG1-OBL4) BCP-ALL were cocultured with human primary BM-MSC and incubated with indicated concentrations of AUR or
ADE for 5 days (in two technical repeats for each drug concentration). Viability of ALL cells was assessed by a hemocytometer using trypan
blue exclusion method. Number of the viable cells of each primograft is presented as percentage of the untreated controls (DMSO). For
each primograft, the data are shown as means +SD. *P < 0.05, **P < 0.01, ***P < 0.0001 by ANOVA with Dunnett’s post hoc test.
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redox-protective cell culture medium supplemented
with 2-mercaptoethanol, we could observe cytotoxic
effects of AUR and ADE to BCP-ALL primografts
harboring MLL-AF4 and BCR-ABL1 translocations
(Fig. 2C). Next, we compared the cytotoxic efficacy
(EC50) of AUR and ADE in BCP-ALL blasts in
monocultures and in corresponding cocultures with
BM-MSC. As presented in Table S2, in every case the
presence of BM-MSC increased resistance to both
AUR and ADE.
These results demonstrate that both BCP-ALL cell
lines and primary cells are sensitive to low micromolar
concentrations of AUR and ADE in vitro. The sensi-
tivity is decreased but not eliminated when the BCP-
ALL cells are grown in a redox-protective medium in
the presence of primary BM-MSC. Our observations
align with the previously reported decreased cytotoxic-
ity of AUR to a CLL cell line MEC-1 grown in the
presence of stromal, nurse-like cells (Fiskus et al.,
2014) and reveal the protective role of stromal cells in
the sensitivity of BCP-ALL cells to the TXN system
inhibitors.
3.3. Auranofin delays leukemia progression in a
patient-derived xenograft model
Since the cytotoxic effect of plasma-achievable concen-
trations of AUR to normal peripheral blood mononu-
clear cells (normal PBMC) was significantly weaker
than ADE (Fig. S2A), we selected AUR for further
studies. AUR exerted higher potency against malig-
nant B cells, as compared to normal B cells (CD19+)
and normal T cells (CD3+) (Fig. S2B). These observa-
tions are in agreement with previously published data
reporting on selectivity of AUR to cancer cells (Fiskus
et al., 2014; Stafford et al., 2018).
Considering that AUR is a clinically used antirheu-
matic agent and is further tested for other indications
including cancer (Roder and Thomson, 2015), we stud-
ied its efficacy against BCP-ALL in vivo using a
patient-derived xenograft model. Since in vitro AUR
was active against BCP-ALL cells representing the
MLL-AF4 subtype derived from an adult patient, the
subtype associated with extremely poor prognosis, we
inoculated these cells to NSG mice. The mice were
treated with AUR when the percentage of human
blasts reached at least 1% murine leukocytes (1.4–
23.9% at day 31 post-leukemic cell inoculation), which
indicates successful leukemia engraftment. AUR signif-
icantly delayed leukemia progression in mice during
3 weeks of the treatment and reduced the numbers of
human blasts observed at the end of the treatment as
compared to controls (Fig. 3A). Moreover, AUR pro-
longed the event-free survival of leukemic mice
(Fig. 3B). These data reveal that AUR attenuates the
progression of MLLr BCP-ALL in vivo.
3.4. Auranofin and adenanthin induce oxidative
stress-mediated cell death in BCP-ALL cell lines
and primary cells
Next, we studied the mechanism of cell death triggered
by AUR and ADE in two BCP-ALL cell lines:
SEM and BV173, representing two genetic subtypes of
Fig. 3. Auranofin attenuates BCP-ALL progression and prolongs the survival of leukemic mice. (A) Primograft cells representing MLLr BCP-
ALL were injected into NSG mice, and leukemia progression was monitored weekly through peripheral blood staining with anti-mCD45, anti-
hCD45, anti-hCD19 antibodies. Starting from day 31 after the cell injection, randomly selected animals were treated with 10 mgkg1 of
AUR or control (DMSO) through intraperitoneal injections, once a day for 3 weeks (5 days of treatment/2 days of break schedule, n = 7 for
each group). Data are presented as a mean fold of human blasts (hCD45+/hCD19+) over murine leukocytes (mCD45+)  SD in time from a
representative experiment. Depicted P value was calculated by ANOVA with Bonferroni’s correction. (B) Kaplan–Meier survival plot
presenting event-free survival of leukemic mice treated with AUR (10 mgkg1, n = 10) or vehicle (DMSO, n = 12) for 14 or 15 days. Data
are pooled from two independent experiments. Depicted P value was calculated by log-rank (Mantel–Cox) test.
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BCP-ALL associated with poor prognosis: MLLr and
BCR-ABL1, respectively. AUR and ADE triggered an
increase in ROS levels (Fig. 4A, Figs S3 and S4A,B),
and 1 mM pyruvate, a hydrogen peroxide scavenger,
partially rescued the cells from AUR and ADE cyto-
toxicity (Fig. 4B, Fig. S4C). Likewise, pretreatment of
the cells with catalase, an enzyme which breaks down
hydrogen peroxide, also reduced AUR cytotoxicity
(Fig. S5). Accordingly, in SEM cells pyruvate or cata-
lase fully abrogated AUR-mediated ROS induction
(Fig. S6). Moreover, both TXN system inhibitors
induced the expression of heme oxygenase-1 (HO-1), a
nuclear factor-like-2 (NRF2)-regulated oxidative stress
biomarker (Fig. 4C, Fig. S4D). ROS accumulation in
cells augments the phosphorylation of histone 2A vari-
ant X (H2A.X), which is a marker of DNA damage
(Li et al., 2006). Accordingly, in AUR/ADE-treated
SEM cells we observed a moderate increase in a phos-
phorylation of H2A.X (Ser139) (Fig. 4D, Fig. S7).
Further, we investigated the levels of oxidative stress
biomarkers in response to AUR in primary BCP-ALL
cells. To this end, we treated primograft cells (repre-
senting MLLr and BCR-ABL1 subtypes) with AUR.
Similar to cell lines, in the primograft cells incubation
with AUR induced the expression of HO-1 and in two
out of three primografts triggered the phosphorylation
of H2A.X (Fig. 5A,B).
Altogether, the above results show that inhibitors of
the TXN system trigger oxidative stress and a moder-
ate cellular oxidative damage, both in BCP-ALL cell
lines and in primary cells. Furthermore, we present in
BCP-ALL cell line models that AUR triggers accumu-
lation of hydrogen peroxide, which aligns with the
hydrogen peroxide-scavenging function of the TXN
Fig. 4. Inhibitors of the TXN system antioxidant enzymes trigger oxidative stress-induced apoptosis in BCP-ALL cell lines. (A) SEM and
BV173 cells were exposed to 1.5 lM of AUR for 1, 2, 4, and 6 h, and ROS levels were accessed by CM-H2-DCFDA. Results are presented
as fold change in mean fluorescence intensity (MFI) over untreated controls. The bars indicate mean + SEM from two independent
experiments. (B) SEM and BV173 cells were pretreated with 1 mM of pyruvate for 30 min and then treated with EC50 and EC80 of AUR.
After 24 h, the number of dead cells was assessed by flow cytometry after staining with propidium iodide (PI). The results are shown as
mean percentage of PI-positive cells + SEM from two independent experiments. (C) SEM cells were treated with EC50 and EC80 of AUR.
The protein levels of the oxidative stress marker, heme oxygenase-1 (HO-1), were assessed by immunoblotting. Graph in the lower panel
presents mean ratio of HO-1 band intensity related to a-tubulin band intensity, calculated by densitometry (IMAGE LAB Software; Bio-Rad
Laboratories). The bars represent means + SEM from two independent experiments. (D) Phosphorylation of H2A.X, a marker of oxidative
DNA damage, was measured using Muse Cell Analyzer (Merck Millipore). SEM cells were treated with EC50 and EC80 of AUR, whereas
cells treated with 200 lM of H2O2 or 100 nM of doxorubicin (DOX) served as positive controls. After 24 h of incubation, cells were stained
with anti-phospho-histone H2A.X (Ser139) and anti-histone H2A.X antibodies and the percentages of activated cells (with phosphorylated
histone H2A.X) were assessed in Muse Cell Analyzer. Data are shown as mean values + SEM from two independent experiments.
*P < 0.05, **P < 0.01, ***P < 0.0001 by t-test in A–D.
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system (Arner, 2017). However, hydrogen peroxide
only partially contributes to AUR-mediated cell death,
which may suggest that other mechanisms are also
involved in cell death mediated by these inhibitors.
3.5. TXN system inhibitors induce ER stress and
unfolded protein response
Auranofin has been shown to induce endoplasmic
reticulum (ER) stress in CLL cells (Fiskus et al.,
2014). Accordingly, we observed an induction of
GRP78, a master regulator of ER stress-induced
unfolded protein response (UPR), at protein and
mRNA levels already after 3 h of incubation with
AUR and ADE (Fig. 6A,B, Fig. S8A,B). Additionally,
AUR induced a phosphorylation of eIF2a (Fig. 6C),
indicating the activation of a protein RNA-like endo-
plasmic reticulum kinase (PERK) and a global transla-
tional block (Harding et al., 2000). We observed
similar yet delayed and less pronounced effect in SEM
cells treated with ADE (Fig. S8C).
The major goal of UPR is to provide a cytoprotec-
tive response to relieve ER stress, yet prolonged or
intensified ER stress leads to apoptosis. C/EBP homol-
ogous protein (CHOP) is a major transcription factor
linking ER stress with the induction of apoptosis
(Zinszner et al., 1998). We observed a significant
induction of CHOP expression in BCP-ALL cells trea-
ted with AUR (Fig. 6D) and, to a lesser extent, also in
cells treated with ADE (Fig. S8D). Accordingly, in
BCP-ALL cells treated with AUR we observed
increased activity of caspases and poly(ADP-ribose)
polymerase (PARP) cleavage, indicating induction of
caspase-dependent apoptotic cell death (Fig. 6E,F).
These results show that inhibition of the TXN system
in BCP-ALL cell lines triggers PERK-dependent, pro-
survival arms of the UPR pathways, such as induction
of GRP78 expression and eIF2a phosphorylation, as
well as induction of CHOP, an element of the switch
from a cytoprotective to death-promoting signaling.
These results align with the previously reported induc-
tion of ER stress by AUR in CLL cells (Fiskus et al.,
2014) and the recently suggested direct requirement of
TXNRD1 for correct protein folding in the ER (Poet
et al., 2017). Nonetheless, we do not exclude the possi-
bility that other UPR-related or UPR-unrelated path-
ways may be involved in AUR-mediated apoptosis.
Therefore, further studies are required to better under-
stand cell death signaling pathways accounting for
AUR cytotoxicity in BCP-ALL cells.
4. Conclusion
Collectively, our results highlight an important, pro-
survival role of the TXN system antioxidant enzymes
in BCP-ALL cells and the efficacy of their inhibitors,
mainly AUR, as potential, novel drugs against BCP-
ALL. We report that increased oxidative stress
biomarkers detected in BCP-ALL patients’ sera are
accompanied by an upregulation of antioxidant
Fig. 5. Auranofin upregulates oxidative stress-related markers in BCP-ALL primograft cells. (A) PG1-ALL2 (BCR-ABL1 BCP-ALL) and PG1-
ALL5 (MLLr BCP-ALL) primograft cells were exposed to indicated concentrations of AUR for 6, 24, and 48 h, and HO-1 levels were
evaluated by immunoblotting. Intensity ratio to a-tubulin is presented under each band, calculated by densitometry. The experiment was
performed once. (B) PG1-ALL2, PG2-OBL9 (MLLr BCP-ALL), and PG1-ALL5 primografts were exposed to AUR (concentrations between
EC50 and EC80) or 200 lM of H2O2 (positive control performed in PG2-OBL9 cells) for 24 h. Following the treatment, the phosphorylation of
H2A.X was evaluated using Muse Cell Analyzer, as described in Fig. 4D and in Materials and methods. The bars represent mean values
(two technical repeats) + SD (n = 1), *P < 0.05, **P < 0.01 by t-test.
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enzymes of the TXN system in BCP-ALL cells, which
may suggest that these enzymes promote survival
under oxidative stress conditions. Accordingly, inhibi-
tors of the TXN system antioxidant enzymes, AUR
and ADE, effectively kill BCP-ALL cell lines and
BCP-ALL primary cells as well as MLLr and BCR-
ABL1 primografts cocultured with BM-MSC. We fur-
ther show that AUR is more selective toward
Fig. 6. Inhibitors of the TXN system antioxidant enzymes trigger ER stress-induced apoptosis. (A, B) For the detection of protein (western
blotting, A) and mRNA (qPCR, B) levels of GRP78, SEM cells were treated with EC50 and/or EC80 of AUR and collected at indicated time
points. Cells exposed to 10 lgmL1 of tunicamycin for 6 h served as a positive control. Densitometry analysis of western blot bands is
shown as a mean intensity normalized to a-tubulin and compared to controls. mRNA levels were detected by qPCR and normalized to a
reference gene, RPL29, and presented as fold change over untreated controls. For both analyses, the bars represent means + SEM from
two independent experiments. (C) To estimate eIF2a phosphorylation, SEM cells were incubated with indicated concentrations of AUR,
lysed at three different time points, and analyzed by western blotting. Cells treated with 10 lgmL1 tunicamycin for 6 h served as a
positive control. For western blot densitometry, p-eIF2a mean intensity was normalized to eIF2a and compared to untreated controls. Each
bar shows mean value +SEM from two independent experiments. (D) SEM cells were treated with EC80 of AUR, and mRNA levels of
CHOP and control, RPL29, were measured by qPCR. Data are shown as fold change as compared to untreated controls. The bars indicate
mean relative expressions + SEM from two independent experiments. (E) SEM cells were exposed to EC20 and EC50 of AUR for 16 h.
Following the treatment, the cells were stained with fluorescent-labeled inhibitor of caspases (FLICA), which allows detecting the cells with
activated caspases using Muse Cell Analyzer. The data are presented as mean values + SEM from two independent repeats. (F) SEM and
BV173 cells were incubated with EC50 and EC80 of AUR and collected after 1, 3, and 6 h. The graph shows representative blots for the
protein levels of full-length and cleaved PARP, and the intensity ratio of cleaved PARP to a-tubulin is depicted under each band. *P < 0.05,
**P < 0.01, ***P < 0.0001 by t-test in A–E.
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malignant B cells and it exerts cytotoxic effects to
BCP-ALL cells in concentrations that are possible to
achieve in human plasma (Blocka et al., 1986). More-
over, AUR delays the progression of MLLr BCP-ALL
in vivo in patient-derived xenograft model, further sub-
stantiating the efficacy of AUR to BCP-ALL cells in
the bone marrow niche. Similar to the previously pub-
lished data obtained in other cancer models (Fiskus
et al., 2014; Liu et al., 2012; Stafford et al., 2018), in
BCP-ALL cells AUR and ADE trigger accumulation
of ROS, and induce oxidative macromolecule damage,
UPR, and apoptosis. Although the induction of oxida-
tive stress at least partially contributes to AUR-
mediated BCP-ALL cell death, the involvement of
UPR pathways in apoptotic signaling requires further
investigations. Moreover, targets other than TXN
system antioxidant enzymes, such as the previously
reported deubiquitinases (Liu et al., 2014) or the
glycolysis enzymes (Hou et al., 2018), could also
contribute to the cytotoxic effect of AUR against BCP-
ALL cells. Altogether, this work unveils TXN system as
a novel target for BCP-ALL therapy and encourages
further preclinical studies aimed at testing the efficacy of
the combinations of TXN system inhibitors with anti-
BCP-ALL chemotherapeutics, as well as with targeted
drugs. Importantly, since AUR is a clinically approved
drug, it could be easily repurposed in combination with
existing drugs into therapy of BCP-ALL.
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